This article is more than 5 years old. Information may no longer be current.

VIDEO: Complete depletion of peripheral B cells with obinutuzumab in lupus nephritis

Issue: December 2019

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WASHINGTON — At ASN Kidney Week, Brad H. Rovin, MD, presented results of the NOBILITY trial, a phase 2 randomized, controlled study of obinutuzumab with mycophenolate and corticosteroids in patients with proliferative lupus nephritis.

He said patients with proliferative lupus nephritis who received obinutuzumab showed a rapid and complete depletion of peripheral B cells without an increase in serious adverse events, serious infections and death compared to the standard of care through week 76 of the study. Patients also had significant improvement in serologies and proteinuria.